Loading...
Market
Pharmaceutical companies' response to Imfinzi approval
2
Resolution / Starting Odds
Launch competitive drug • 33%
File lawsuit against AstraZeneca • 33%
No significant response • 33%
Press releases and news articles from pharmaceutical companies
Story
FDA Approves Imfinzi Combo for dMMR Advanced Endometrial Cancer
Jun 17, 2024, 08:12 AM
The U.S. Food and Drug Administration (FDA) has approved the use of durvalumab in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This approval, announced on June 14, is based on the Duo-E subgroup analysis. Durvalumab, marketed as IMFINZI®, is produced by AstraZeneca (AZN).
View original story
Similar markets
Launch new competing drug • 25%
Increase marketing for existing drugs • 25%
File a lawsuit or regulatory complaint • 25%
No significant response • 25%
Merck & Co. • 25%
Bristol-Myers Squibb • 25%
Roche • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
AstraZeneca/Daiichi Sankyo • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other • 25%
Acknowledge and propose further studies • 25%
Deny correlation and defend vaccine safety • 25%
Announce new vaccine formulations • 25%
No official response • 25%
Yes • 50%
No • 50%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%